Wed Sep 25 08:56:00 UTC 2024: ## Cancer Drug Developers Fuel Stock Market Surge: Summit Therapeutics and Instil Bio Soar Over 700%
**New York, NY** – Two cancer drug developers, Summit Therapeutics and Instil Bio, have seen their stock prices skyrocket over 700% in 2024, attracting investors seeking dramatic gains. The surge is fueled by the potential of their new drug candidates, which could rival leading cancer immunotherapy Keytruda from Merck.
Summit Therapeutics, whose stock has risen by 739.5% this year, is developing ivonescimab, a bispecific antibody that targets both PD-1 (programmed death ligand-1) and VEGF-A (vascular endothelial growth factor A). Early clinical trial data shows ivonescimab outperforming Keytruda in treating lung cancer.
Instil Bio, with a stock surge of 814% in 2024, is developing SYN-2510, another bispecific PD-1/VEGF antibody. While head-to-head data against Keytruda is not yet available, its similarity to ivonescimab has driven investor interest.
Both companies are still in pre-commercial stages, and their future success is uncertain. However, the potential for these drugs to become major cancer treatments has driven investor enthusiasm.
**Ivonescimab: A Potential Blockbuster?**
Summit Therapeutics’ ivonescimab has shown promising results in clinical trials for lung cancer. In a phase 3 trial, ivonescimab demonstrated a 49% reduction in the risk of disease worsening compared to Keytruda. The company is also conducting a trial in North America combining ivonescimab with chemotherapy for first-line lung cancer patients.
**SYN-2510: A Latecomer with Potential**
Instil Bio’s SYN-2510 is in earlier stages of development compared to ivonescimab. The company plans to initiate late-stage clinical trials in China and the US this year.
**Investor Caution Advised**
Despite the potential, both companies face significant risks. Their success hinges on the outcome of further clinical trials. The high valuations of these companies, particularly Summit Therapeutics, have raised concerns about their sustainability. Investors should approach these stocks with caution and only invest what they can afford to lose.
**The Motley Fool’s Perspective**
The Motley Fool, a financial advisory firm, has not included Summit Therapeutics in its list of top 10 stocks to buy. However, the firm acknowledges the potential for these drug developers to produce significant returns in the future.
The future of these companies and their stock prices will depend on the continued success of their respective drug candidates in clinical trials. Investors should carefully consider the risks and potential rewards before investing in these high-growth but volatile companies.
First Piper 